Campbell & CO Investment Adviser LLC Takes Position in Collegium Pharmaceutical, Inc. $COLL

Key Points

• Campbell & CO Investment Adviser LLC has acquired a new position in Collegium Pharmaceutical, purchasing 47,568 shares valued at approximately $1,420,000, representing around 0.15% of the company.
• Wall Street analysts are forecasting growth for Collegium Pharmaceutical, with ratings ranging from "neutral" to "strong-buy" and a consensus target price of $42.33.
• Collegium Pharmaceutical has approved a $150 million stock repurchase plan, indicating management's belief that its shares are undervalued.

Campbell & CO Investment Adviser LLC purchased a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 47,568 shares of the specialty pharmaceutical company's stock, valued at approximately $1,420,000. Campbell & CO Investment Adviser LLC owned approximately 0.15% of Collegium Pharmaceutical at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Wealthquest Corp bought a new position in Collegium Pharmaceutical during the 1st quarter valued at $62,000. Virtus Fund Advisers LLC raised its stake in shares of Collegium Pharmaceutical by 30.5% in the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company's stock valued at $69,000 after purchasing an additional 565 shares in the last quarter. FORA Capital LLC acquired a new stake in shares of Collegium Pharmaceutical in the 4th quarter valued at about $223,000. Allspring Global Investments Holdings LLC bought a new position in shares of Collegium Pharmaceutical during the first quarter worth about $244,000. Finally, Brevan Howard Capital Management LP acquired a new position in Collegium Pharmaceutical in the fourth quarter worth about $281,000.

Wall Street Analysts Forecast Growth

COLL has been the subject of several research analyst reports. Piper Sandler reissued a "neutral" rating and issued a $37.00 price objective (up from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. Wall Street Zen upgraded Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Finally, HC Wainwright raised Collegium Pharmaceutical to a "strong-buy" rating and set a $44.00 price target on the stock in a research report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $42.33.

Collegium Pharmaceutical Stock Down 0.9%

Shares of Collegium Pharmaceutical stock opened at $38.77 on Tuesday. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of 37.28 and a beta of 0.68. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $42.29. The company has a current ratio of 1.18, a quick ratio of 1.10 and a debt-to-equity ratio of 3.27. The business's 50 day simple moving average is $32.60 and its 200-day simple moving average is $30.10.

Collegium Pharmaceutical announced that its Board of Directors has approved a stock repurchase plan on Monday, July 7th that permits the company to repurchase $150.00 million in outstanding shares. This repurchase authorization permits the specialty pharmaceutical company to reacquire up to 15.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's management believes its shares are undervalued.

Insiders Place Their Bets

In related news, Director Gino Santini sold 5,405 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $37.19, for a total value of $201,011.95. Following the sale, the director owned 95,042 shares of the company's stock, valued at $3,534,611.98. This trade represents a 5.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Scott Dreyer sold 16,389 shares of the business's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $38.21, for a total transaction of $626,223.69. Following the transaction, the executive vice president directly owned 103,613 shares of the company's stock, valued at $3,959,052.73. The trade was a 13.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 44,915 shares of company stock valued at $1,614,825 over the last three months. Company insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.